Click Therapeutics conducted a pivotal randomized, double-blind, controlled, decentralized, study of CT-132 for the preventive treatment of migraine, ReMMi-D (Reduction in Monthly Migraine Days, NCT05853900). At completion of the study, CT-132 showed a statistically significant reduction in monthly migraine days (MMDs) following 12 weeks of treatment compared to sham, (n=568, ITT population, -0.9 MMDs, p=0.005), with the treatment arm experiencing -3.04 MMDs by end of treatment. Further, CT-132 improved Migraine-Specific Quality-of-Life Questionnaire (MSQ) from as early as 4 weeks and through weeks 8 and 12 (p<0.001 at all time points), and the treatment group experienced categorical improvement in the Migraine Disability Assessment (MIDAS) at the end of treatment (p=0.002). Additionally, patients reported improvement in their health due to CT-132 as measured by the Patient Global Impression - Change (PGI-C) at the end of the trial (p<0.001). Engagement and adherence were high and sustained over the full 12-week duration of the treatment. Both the intervention and sham groups demonstrated nearly 100% median completion of daily tasks. CT-132 was well tolerated and exhibited no treatment-related adverse events. In addition, the recently completed ReMMiD-C bridging study (NCT06004388) provided supportive information to the pivotal study in patients taking the new-class of migraine-specific medications, CGRP inhibitors.